Market news

Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...

Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross...

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17,

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial...

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

Lisata Therapeutics (LSTA) shares were down about 17% in Friday afternoon trading after the company

Lisata Therapeutics stock fell after hours after updating investors on its pending acquisition and tender offer.

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)